BACKGROUND: CpG-containing oligodeoxynucleotides (CpG-ODNs) are potent inhibitors of T helper 2 mediated allergic airway disease in sensitised mice challenged with allergen. A single treatment has transient effects but a limited series of treatments has potential to achieve clinically meaningful sustained inhibition of allergic airway disease. OBJECTIVE: To optimise the treatment regimen for sustained efficacy and to determine the mechanisms of action in mice of an inhaled form of CpG-ODN being developed for human asthma treatment. METHODS: We set up a chronic allergic-asthma model using ragweed-sensitised mice exposed weekly to intranasal ragweed. Using this model, the effects of a limited series of weekly intranasal 1018 ISS (CpG-ODN; B-class) treatments were evaluated during treatment and for several weeks after treatments had stopped but weekly allergen exposures continued. Treatment efficacy was evaluated by measuring effects on lung T helper 2 cytokines and eosinophilia, and lung dendritic cell function and T-cell responses. RESULTS: Twelve intranasal 1018 ISS treatments induced significant suppression of bronchoalveolar lavage eosinophilia and interleukin 4, 5 and 13 levels. This suppression of allergic T helper 2 parameters was maintained through 13 weekly ragweed exposures administered after treatment cessation. Subsequent experiments demonstrated that at least five treatments were required for lasting suppression. Although CpG-ODN induced moderate T helper 1 responses, suppression of allergic airway disease did not require interferon γ but was associated with induction of a regulatory T-cell response. CONCLUSIONS: A short series of CpG-ODN treatments results in sustained suppression of allergic lung inflammation induced by a clinically relevant allergen. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: CpG-containing oligodeoxynucleotides (CpG-ODNs) are potent inhibitors of T helper 2 mediated allergic airway disease in sensitised mice challenged with allergen. A single treatment has transient effects but a limited series of treatments has potential to achieve clinically meaningful sustained inhibition of allergic airway disease. OBJECTIVE: To optimise the treatment regimen for sustained efficacy and to determine the mechanisms of action in mice of an inhaled form of CpG-ODN being developed for human asthma treatment. METHODS: We set up a chronic allergic-asthma model using ragweed-sensitised mice exposed weekly to intranasal ragweed. Using this model, the effects of a limited series of weekly intranasal 1018 ISS (CpG-ODN; B-class) treatments were evaluated during treatment and for several weeks after treatments had stopped but weekly allergen exposures continued. Treatment efficacy was evaluated by measuring effects on lung T helper 2 cytokines and eosinophilia, and lung dendritic cell function and T-cell responses. RESULTS: Twelve intranasal 1018 ISS treatments induced significant suppression of bronchoalveolar lavage eosinophilia and interleukin 4, 5 and 13 levels. This suppression of allergic T helper 2 parameters was maintained through 13 weekly ragweed exposures administered after treatment cessation. Subsequent experiments demonstrated that at least five treatments were required for lasting suppression. Although CpG-ODN induced moderate T helper 1 responses, suppression of allergic airway disease did not require interferon γ but was associated with induction of a regulatory T-cell response. CONCLUSIONS: A short series of CpG-ODN treatments results in sustained suppression of allergic lung inflammation induced by a clinically relevant allergen. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: D H Broide; G Stachnick; D Castaneda; J Nayar; M Miller; J Y Cho; M Roman; J Zubeldia; T Hayashi; E Raz; T Hyashi Journal: J Clin Immunol Date: 2001-05 Impact factor: 8.317
Authors: Peter S Creticos; John T Schroeder; Robert G Hamilton; Susan L Balcer-Whaley; Arouna P Khattignavong; Robert Lindblad; Henry Li; Robert Coffman; Vicki Seyfert; Joseph J Eiden; David Broide Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Krisztian Nemeth; Andrea Keane-Myers; Jared M Brown; Dean D Metcalfe; James D Gorham; Jared D Gorham; Virgilio G Bundoc; Victor G Bundoc; Marcus G Hodges; Ivett Jelinek; Satish Madala; Sarolta Karpati; Eva Mezey Journal: Proc Natl Acad Sci U S A Date: 2010-03-15 Impact factor: 11.205
Authors: Meri K Tulic; Pierre-Olivier Fiset; Pota Christodoulopoulos; Patrice Vaillancourt; Martin Desrosiers; François Lavigne; Joseph Eiden; Qutayba Hamid Journal: J Allergy Clin Immunol Date: 2004-02 Impact factor: 10.793
Authors: Michelle V Fanucchi; Edward S Schelegle; Gregory L Baker; Michael J Evans; Ruth J McDonald; Laurel J Gershwin; Eyal Raz; Dallas M Hyde; Charles G Plopper; Lisa A Miller Journal: Am J Respir Crit Care Med Date: 2004-08-11 Impact factor: 21.405
Authors: Leonie S van Rijt; Steffen Jung; Alex Kleinjan; Nanda Vos; Monique Willart; Catherine Duez; Henk C Hoogsteden; Bart N Lambrecht Journal: J Exp Med Date: 2005-03-21 Impact factor: 14.307
Authors: Allison K Ehrlich; Olga L Fernández; Daniel Rodriguez-Pinto; Tiago M Castilho; Maria J Corral Caridad; Karen Goldsmith-Pestana; Nancy Gore Saravia; Diane McMahon-Pratt Journal: Infect Immun Date: 2017-02-23 Impact factor: 3.441
Authors: Chantal Meulenbroeks; Jaco J van der Lugt; Nathalie M A van der Meide; Ton Willemse; Victor P M G Rutten; Dietmar M W Zaiss Journal: PLoS One Date: 2015-04-22 Impact factor: 3.240
Authors: Marie Ballester; Laura Jeanbart; Alexandre de Titta; Chiara Nembrini; Benjamin J Marsland; Jeffrey A Hubbell; Melody A Swartz Journal: Sci Rep Date: 2015-09-21 Impact factor: 4.379
Authors: Stephen Delaney; Mark Biffen; Justine Maltby; John Bell; Sara Asimus; Ajay Aggarwal; Maarten Kraan; David Keeling Journal: BMJ Open Respir Res Date: 2016-02-23